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Medulloblastoma is the most common brain tumor in children, with 500 new diagnoses in the United 
States each year. The majority of genetic changes that lead to formation of this brain tumor are 
largely unknown aside from changes in a few key developmental pathways. Former graduate 
student Dr. Joyoti Dey, working in the laboratory of Dr. James Olson (Clinical Research Division), 
found a surprising new player in brain tumor formation with a long history of research at Fred 
Hutchinson Cancer Research Center. "MyoD was discovered here at the Hutch by Dr. Hal 
Weintraub's team.  It's known as a master regulator of muscle differentiation," according to Dr. 
Olson.  "Who would have imagined that it plays a role in normal brain development and in 
suppressing the formation of medulloblastoma brain tumors?" 
To find novel players in brain tumor formation, collaborator Dr. Michael Taylor’s research team at 
The Hospital for Sick Children in Toronto, Canada took a mouse model of medulloblastoma and 
introduced a genetic tool called aSleeping Beauty transposon, so named because the system was 
resurrected from an extinct transposon. Transposons are small pieces of DNA that can jump from 
one site in DNA to another in a cut-and-paste fashion with the aid of the enzyme transposase. The 
DNA transposons insert almost randomly throughout the genome when introduced into cells, and 
these insertions can disrupt the expression of genes, allowing researchers to infer the functions of 
their encoded proteins. Dey et al. found that loss of one copy ofMyoD accelerated tumor formation in 
the Sonic Hedgehog (Shh)-driven mouse model of brain cancer. 
To confirm their findings, the researchers then looked at MyoD genetic changes in human 
medulloblastomas. No DNA mutations were observed in 310 sequenced tumors; however, the 
chromosomal region encoding MyoD was deleted in 6% of tumors across molecular subtypes. 
Human medulloblastoma tumors are classified in four subtypes, based on the disruption of two 
developmental pathways, the Shh pathway and the WNT pathway, or two other poorly characterized 
subtypes. Previously, the Olson lab created two mouse models of medulloblastoma with two 
different activating mutations in the Smoothened gene,SmoA1 and SmoA2, which in turn activate the 
Shh pathway (Dey et al., 2012). Deleting one copy of MyoD in these mice accelerated tumor 
formation and decreased survival (see figure), supporting a role for MyoD as a tumor suppressor in 
brain tumors. 
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Importantly, the researchers discovered that MyoD protein was also present in the developing 
normal mouse brain, specifically in cells of the cerebellum that are thought to be precursors to Shh-
driven tumors (see figure). MyoD expression is silenced in normal differentiated cerebellar cells, but 
MyoD expression was increased in the immature proliferating tumor cells in 
bothSmoA1 and SmoA2 medulloblastoma mouse models. The expression of MyoD in brain tumor 
cells occurred as a result of tumorigenesis, since expression was not increased in the non-tumor 
cells of the SmoA1 and SmoA2 mice. Expression of some tumor suppressors is decreased in cancer 
cells, while expression is increased for others in rapidly growing cancer cells in an attempt, albeit 
unsuccessfully, to control growth or differentiation of cells. The latter seemed to be the case for 
MyoD in the mouse tumors. However, the fact that a single molecule in a complex neoplastic 
network involving a plethora of disrupted pathways can hinder tumorigenesis by itself is 
fascinating.  Rarely, human medulloblastoma cells have shown acquisition of features of non-
neuronal tissues, including the expression of genes associated with muscle. Dey et al. found 36% of 
human tumors showed MyoD expression. 
Exactly how MyoD functions as a tumor suppressor has yet to be determined, though it is not 
through controlling genes involved in muscle differentiation. MyoD can also regulate the cell cycle, 
and as a transcription factor it regulates the expression of thousands of different genes that could be 
influencing tumor development. Intriguingly, expression of MyoD is silenced in other solid tumors, 
such as prostate and colon cancer, yet no function had been described for this gene in cancer 
formation until this exciting study revealed its tumor suppressor function.  
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Image provided by Dr. Joyoti Dey 
MyoD (green color in top images) is expressed in the developing 
mouse cerebellum, silenced in the normal adult brain, and highly 
expressed in medulloblastoma tumors. Genetic loss of MyoD in 
mouse models of medulloblastoma leads to accelerated 
tumorigenesis, establishing its function as a tumor suppressor. 
 
